Clinical Trials Logo

Clinical Trial Summary

Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography, cardiac magnetic resonance, pressure guide wire, intravascular ultrasound

Clinical Trial Description

Heart transplant survival has barely improved in the last decades and unsatisfactory for a large proportion of heart transplant recipients. The development of leukocyte antigen antibodies (anti-HLA) in the post-transplant patient is associated to the main causes of graft dysfunction. The mechanisms of this damage are unclear and there's no effective treatment. The investigators aim is to identify early markers of graft injury through a complete morphological and functional evaluation with histological analysis, immunological assays, advanced imaging techniques and invasive evaluation of coronary vasculature in patients with anti-HLA compared to matching controls. The investigators propose a cross-sectional study within a large heart transplant cohort. This is a multicentric observational multimodal study. The investigators aim is to establish early characteristics of antibody mediated damage and set the bases for future studies looking for new treatment targets. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05184426
Study type Observational
Source Hospital Universitario 12 de Octubre
Status Active, not recruiting
Start date April 1, 2021
Completion date September 30, 2029

See also
  Status Clinical Trial Phase
Completed NCT02533596 - Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange N/A
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Not yet recruiting NCT05021484 - Felzartamab in Late Antibody-Mediated Rejection Phase 2
Suspended NCT02120482 - Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study N/A
Recruiting NCT03744910 - Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Phase 3
Not yet recruiting NCT04561986 - TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients Phase 3
Terminated NCT03221842 - Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Phase 3
Terminated NCT01895127 - Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Phase 2
Completed NCT02013037 - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Phase 3
Recruiting NCT03737136 - Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR N/A
Recruiting NCT04541914 - Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Recruiting NCT04897438 - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection N/A
Recruiting NCT05004493 - Biorepository and Registry for Plasma Exchange Patients
Recruiting NCT04026087 - Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Active, not recruiting NCT03994783 - Transplant Antibody-Mediated Rejection: Guiding Effective Treatments Phase 3
Recruiting NCT04368962 - DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Completed NCT03444103 - A Pilot Trial of Clazakizumab in Late ABMR Phase 2
Not yet recruiting NCT05140018 - Incidence, Course and Outcome of ABMR in Kidney Transplantation
Completed NCT03408158 - HPA Antibodies and the Distribution of Antigen and Antibodies N/A